TGE/PEDV

Transmissible gastroenteritis and porcine epidemic diarrhea vaccines protect swine against two devastating coronavirus diseases that cause severe enteric disease with potentially catastrophic mortality in neonatal piglets. Transmissible gastroenteritis virus and porcine epidemic diarrhea virus are alphacoronaviruses that infect intestinal epithelial cells, causing villous atrophy and severe malabsorptive diarrhea. In naive breeding herds, these viruses can cause one hundred percent morbidity with mortality rates approaching one hundred percent in piglets under two weeks of age, making them among the most economically destructive diseases affecting modern swine production. The introduction of PEDV to North America in 2013 resulted in the loss of millions of piglets and fundamentally changed biosecurity practices across the industry.

The mechanism of protection for TGE and PEDV vaccines relies primarily on stimulating lactogenic immunity in sows, which then transfer protective antibodies to piglets through milk. Unlike many other diseases where systemic antibody provides protection, coronavirus infections of the gut require local mucosal immunity for effective protection. Maternal immunoglobulin A antibodies secreted into milk neutralize virus in the piglet intestinal lumen, preventing epithelial infection and disease development. This lactogenic immunity model means that sow vaccination timing relative to farrowing critically determines piglet protection, and vaccines must stimulate gut-associated lymphoid tissue immunity to be optimally effective.

Vaccine options for TGE and PEDV have evolved significantly since PEDV emergence, though availability and regulatory status vary by product and region. Traditional TGE vaccines have been available for decades as modified live or killed products, though their effectiveness against severe disease challenge has been debated. PEDV vaccines initially entered the market through conditional licensure and autogenous vaccine pathways, with RNA particle vaccine technology representing a newer platform. Some products combine TGE and PEDV antigens, while others include porcine deltacoronavirus, another emerging enteric pathogen. The antigenic relationship between TGE virus and porcine respiratory coronavirus complicates vaccine-induced versus natural immunity interpretation.

Regulatory oversight of coronavirus vaccines for swine involves USDA Center for Veterinary Biologics for licensed products, with autogenous vaccines produced under state regulatory frameworks. The conditional license pathway accelerated PEDV vaccine availability during the initial outbreak, though demonstration of efficacy remained challenging. These vaccines require veterinary prescription and should be components of comprehensive coronavirus control programs integrating strict biosecurity, sanitation, gilt acclimation protocols, and strategic feedback exposure programs when appropriate. Understanding the limitations of current vaccines while optimizing their use within integrated programs represents the practical reality of coronavirus management in commercial swine production.

The primary indication for TGE and PEDV vaccines is protection of neonatal piglets against fatal enteric coronavirus disease through vaccination of breeding females. Direct vaccination of piglets is not practical or effective because disease occurs in the first days of life before active immunity can develop, and the lactogenic immunity model requires maternal antibody delivery through milk rather than systemic immunization of the piglet. Sow vaccination programs aim to stimulate robust milk antibody secretion that continues throughout lactation, providing continuous passive protection to nursing piglets during their period of maximum susceptibility. This strategic approach shifts vaccination focus from the at-risk individual to the protective dam.

Breeding herd mass vaccination finds application when coronavirus introduction threatens naive populations or when endemic circulation requires ongoing immunity maintenance. Initial outbreak response in previously negative herds may combine vaccination with controlled exposure to accelerate whole-herd immunity development, with vaccines serving to boost and standardize immune responses across the breeding population. Maintenance vaccination in endemic herds ensures consistent immunity across parities and sustains milk antibody levels despite natural immunity waning over time. The relative contribution of vaccination versus natural exposure to herd immunity varies with circulation dynamics and management practices.

Gilt acclimation programs incorporate TGE and PEDV vaccination as a critical component of preparing incoming replacement breeding stock for pathogen exposures present in the destination herd. Gilts originating from coronavirus-negative sources must develop immunity before farrowing their first litters, or their piglets will lack protective maternal antibody. Acclimation protocols typically combine vaccination with controlled feedback exposure using intestinal homogenates from infected piglets or virus-spiked material, timing exposures to ensure immunity development before breeding or early gestation. Vaccination alone without feedback exposure may provide insufficient protection, particularly against highly virulent PEDV strains.

Emergency response to acute coronavirus outbreaks represents an important application of vaccination programs, though expectations must account for the time required for immunity development. Sows vaccinated during an active outbreak will not have protective milk antibody levels immediately, and piglets born before immunity develops will remain susceptible. However, vaccination during outbreaks accelerates herd immunity development and may reduce outbreak duration compared to natural exposure alone. Mass vaccination also establishes a foundation for ongoing protection that extends beyond the acute outbreak period. Combining vaccination with intensive sanitation, biosecurity reinforcement, and strategic piglet support measures addresses both immediate and longer-term coronavirus challenges.

AutoFgenous vaccines provide farm-specific coronavirus protection when commercial products inadequately match circulating strains or when regulatory limitations restrict commercial product availability. The genetic diversity among circulating PEDV strains, including highly virulent and milder variant strains, may exceed what commercial vaccines comprehensively address. Autogenous vaccines manufactured from virus isolated from the specific farm experiencing challenges offer theoretically optimal strain matching, though production timelines and potency demonstration limitations present practical challenges. Combining autogenous and commercial vaccines may provide broader protection than either approach alone.

Dosing protocols for TGE and PEDV vaccines emphasize strategic timing relative to farrowing to maximize milk antibody concentrations during the critical neonatal period. Most products recommend vaccination three to six weeks before farrowing for primary immunization, allowing sufficient time for antibody development and mammary gland trafficking. A second dose two to three weeks before farrowing boosts antibody levels immediately before lactation begins. This timing ensures peak milk antibody concentrations coincide with early lactation when piglets consume the highest proportion of their nutrition as milk and face the greatest coronavirus susceptibility. Products vary in specific timing recommendations, and label directions should guide protocol development.

Primary vaccination of naive gilts or sows requires two doses separated by three to four weeks to establish baseline immunity before the pre-farrowing boost takes effect. Animals without prior coronavirus exposure or vaccination have no immunological memory to activate, necessitating the complete primary series for adequate response. This extended timeline means gilt acclimation programs must begin sufficiently early to complete primary vaccination before pregnancy or early enough in gestation to permit the pre-farrowing boost schedule. Batch farrowing systems facilitate coordinated vaccination timing across breeding groups.

Booster vaccination of previously immunized sows maintains immunity across subsequent parities, with most protocols recommending vaccination before each farrowing. Natural exposure between farrowings may supplement vaccine-induced immunity in endemic herds, but reliance on field exposure alone produces variable immunity that may leave some litters inadequately protected. Consistent pre-farrowing vaccination standardizes immunity across the sow herd regardless of individual natural exposure histories. Annual mass herd vaccination provides an alternative to individual pre-farrowing vaccination in some programs, though this approach may not optimize protection for all farrowing dates.

Administration technique follows standard injectable vaccine practices with intramuscular injection in the neck musculature. Dose volumes typically range from one to two milliliters depending on product, and appropriate needle selection based on animal size ensures proper intramuscular deposition. Injection sites should be clean and dry, and vaccines should be at room temperature before administration to reduce injection site reactions. Multi-dose vials should be used according to manufacturer specifications regarding duration after first puncture. Vaccination records documenting product, dose, administration date, and animal identification support program management and troubleshooting.

No withdrawal times apply to TGE and PEDV vaccines in swine, as these biological products do not produce tissue residues of food safety concern. Injection site reactions could theoretically cause carcass defects if sows are subsequently culled for slaughter, though this concern is minimal with proper injection technique in the neck. Sows may be marketed at any time following vaccination without withdrawal restrictions. The vaccines do not affect milk consumption by humans since pig milk is not used for human food.

Feedback exposure programs, while not vaccines per se, often accompany vaccination in TGE and PEDV control and merit discussion in the context of dosage and administration. Controlled exposure using intestinal material from infected piglets provides live virus exposure that stimulates mucosal immunity more effectively than injectable killed vaccines alone. Feedback protocols must be carefully controlled to ensure appropriate exposure without overwhelming naive animals, and biosecurity measures must prevent inadvertent spread to unintended populations. Combining vaccination with feedback optimizes both humoral and mucosal immune responses in comprehensive coronavirus acclimation programs.

TGE and PEDV vaccines are generally well-tolerated when administered according to label directions, with most animals showing no adverse effects beyond mild transient soreness at injection sites. The inactivated virus and adjuvant components necessary for immunogenicity carry inherent potential for local inflammatory reactions and systemic immune activation that manifest as recognizable side effects in some individuals. Understanding normal post-vaccination responses helps distinguish expected effects from pathological conditions requiring intervention and supports appropriate expectations for vaccination program implementation.

Injection site reactions represent the most commonly observed adverse effects, presenting as localized swelling, firmness, warmth, or discomfort in the neck musculature following vaccination. These reactions reflect local inflammatory responses to vaccine adjuvants designed to enhance immunogenicity and are generally self-limiting. Most injection site reactions remain small, measuring several centimeters or less in diameter, and resolve within one to two weeks without treatment. Proper injection technique including appropriate needle selection, clean injection sites, and correct intramuscular placement minimizes reaction severity. Injection in the neck rather than ham or loin preserves carcass value if animals are subsequently culled.

Systemic reactions following coronavirus vaccination may include transient fever, reduced appetite, and decreased activity lasting twenty-four to forty-eight hours. These responses reflect systemic cytokine release accompanying effective immune activation and should not be confused with disease processes. Mild systemic reactions may correlate with robust immune response development, though severe or prolonged reactions warrant veterinary evaluation. Pregnant sows experiencing significant post-vaccinal reactions should be monitored for any effects on pregnancy, though controlled studies with licensed products have not demonstrated reproductive impacts when vaccines are used as directed.

Anaphylactic reactions can occur with any injectable biological product, though they are uncommon with coronavirus vaccines. Signs of anaphylaxis in swine include acute respiratory distress, cyanosis, vomiting, urticaria, and collapse that may progress to death without intervention. Epinephrine should be available during vaccination sessions, and personnel should be trained to recognize anaphylaxis and administer appropriate emergency treatment. Animals experiencing anaphylaxis should not receive subsequent doses of the implicated product, and alternative vaccines or management strategies should be considered for hypersensitive individuals.

Reproductive safety concerns have received attention given that coronavirus vaccines are specifically indicated for use in pregnant sows. Extensive use of these vaccines in breeding populations has not revealed patterns of reproductive problems attributable to vaccination when products are used according to label directions. Theoretical concerns about fever-induced pregnancy loss have prompted some practitioners to recommend avoiding vaccination during the first trimester when embryonic loss is most likely from environmental stressors. Most protocols target the final third of gestation when pregnancy is well-established and pre-farrowing immunity optimization is the goal.

Clinical illness at the time of scheduled vaccination contraindicates TGE and PEDV vaccine administration, as sick animals may experience exacerbated disease, fail to develop adequate immune responses, or present diagnostic confusion between vaccine effects and underlying pathology. Sows exhibiting fever, respiratory distress, lameness, or signs of systemic illness should be excluded from vaccination until recovered. The physiological stress of concurrent disease diverts metabolic resources from immune response development, potentially compromising vaccine efficacy. Treatment of primary conditions takes precedence, with vaccination rescheduled following recovery.

Hypersensitivity to previous vaccine doses or known hypersensitivity to vaccine components contraindicates revaccination with the same product. Animals that have experienced anaphylaxis, severe systemic reactions, or persistent injection site pathology following coronavirus vaccination should not receive additional doses of the implicated product. Careful observation following initial doses identifies hypersensitive individuals before subsequent exposure. Alternative vaccine products with different formulations or adjuvant systems may be tolerated by animals hypersensitive to specific vaccines, though cautious administration with emergency treatment available is advisable.

Severe debilitation or immunosuppression from concurrent disease processes, malnutrition, or immunosuppressive drug therapy may prevent adequate vaccine responses and warrants evaluation before vaccination. Sows in poor body condition, experiencing concurrent PRRS or PCV2 disease, or receiving corticosteroid therapy may not develop protective immunity following vaccination. Addressing underlying conditions before vaccination optimizes the likelihood of successful immunization. In situations where vaccination cannot be delayed, awareness of potentially suboptimal responses guides expectations and may prompt additional management interventions.

Vaccination timing too close to farrowing may not allow sufficient time for optimal immunity development and represents a relative contraindication to standard protocols. Sows vaccinated less than two weeks before farrowing will have lower milk antibody concentrations during early lactation than those vaccinated with appropriate pre-farrowing timing. While late vaccination provides some benefit compared to no vaccination, it does not optimize piglet protection. Emergency situations may necessitate vaccination despite suboptimal timing, with expectations adjusted accordingly. Similarly, vaccination too early in gestation may result in immunity waning before farrowing, particularly with single-dose protocols.

Immunosuppressive agents including corticosteroids at anti-inflammatory or immunosuppressive doses interfere with vaccine-induced immunity development and should not be administered concurrently with TGE and PEDV vaccination. Glucocorticoids suppress multiple immune response pathways, reducing antibody production and memory cell development necessary for protective immunity. Dexamethasone, prednisolone, and other corticosteroids commonly used in swine practice should be avoided around vaccination periods, with separation of at least several days before and after vaccine administration recommended. Animals requiring ongoing corticosteroid therapy for medical conditions present challenges for vaccination program implementation.

Antimicrobial agents do not directly interfere with inactivated coronavirus vaccines, as these products contain no viable organisms whose replication could be inhibited by antibiotics. Concurrent antibiotic therapy for unrelated conditions can generally proceed without modification to vaccination schedules. However, systemic illness requiring antibiotic treatment suggests the animal may be suboptimal for vaccination due to concurrent disease rather than direct drug-vaccine interaction. Animals being treated for infections should be evaluated individually regarding vaccination appropriateness, with consideration of disease severity and expected recovery timeline.

Interactions with other vaccines require consideration when coronavirus vaccination is incorporated into comprehensive sow herd immunization programs. Simultaneous administration of multiple vaccines at different injection sites is commonly practiced for logistical efficiency and is generally acceptable, though additive systemic reactions may occur. Scheduling separation between different vaccines when possible optimizes individual immune responses. Specific interactions between coronavirus vaccines and other swine vaccines have not been extensively characterized, but general principles of avoiding immunological competition between simultaneously administered complex antigens suggest benefits to temporal separation when practically achievable.

Feedback exposure programs involving live virus administration interact with vaccination programs in complex ways that require integrated planning. Live virus exposure following vaccination may boost responses to vaccine-matched antigens while potentially introducing antigenically distinct strains. Timing of feedback relative to vaccination affects whether responses are additive or interfering. Programs combining vaccination with feedback typically complete vaccination before feedback exposure, allowing vaccine-induced immunity development before challenge with virulent material. Veterinary guidance in designing integrated vaccination and feedback protocols optimizes the contribution of each component to overall herd immunity.

Human safety precautions apply to TGE and PEDV vaccine handling, though these coronaviruses are not zoonotic and do not infect humans. The primary human health concerns involve vaccine components including adjuvants and preservatives that could cause local tissue reactions following accidental self-injection. Personnel should use appropriate personal protective equipment including gloves and should avoid needlestick injuries during vaccine administration. Accidental self-injection warrants medical evaluation, with vaccine product information provided to healthcare providers. Proper sharps handling and disposal prevents injuries during and after vaccination sessions.

Biosecurity implications of coronavirus vaccination programs require careful attention, particularly regarding the interface between vaccination and controlled exposure protocols. Feedback exposure using virus-containing material inherently involves pathogen handling that could result in inadvertent spread to unvaccinated populations or introduction to previously negative herds if biosecurity lapses occur. Strict separation between coronavirus-positive and coronavirus-negative production flows, thorough cleaning and disinfection of equipment used in feedback programs, and personnel protocols preventing cross-contamination maintain biosecurity integrity. Vaccination alone without feedback avoids these biosecurity complexities but may provide suboptimal protection.

Vaccine efficacy limitations must be clearly understood when implementing TGE and PEDV vaccination programs. Current vaccines do not provide complete protection against all coronavirus challenges, particularly highly virulent PEDV strains in completely naive populations. The lactogenic immunity model requires optimal sow vaccination timing, adequate colostrum consumption by piglets, and continued nursing throughout the susceptibility period. Piglets that fail to nurse adequately, are cross-fostered to improperly vaccinated sows, or wean early may lack protective antibody despite sow vaccination. Setting realistic expectations prevents false confidence in vaccination as a standalone coronavirus solution.

Emergency vaccine use during active outbreaks requires understanding that protection will not be immediate. Sows vaccinated after outbreak onset require weeks to develop protective milk antibody, and piglets born before immunity develops will remain susceptible to severe disease. Outbreak response vaccination establishes the foundation for herd immunity but does not immediately halt piglet mortality. Integrating vaccination with intensive piglet support, including supplemental nutrition, thermal support, and management of secondary infections, addresses immediate welfare concerns while vaccination provides longer-term solutions. Communication with farm personnel regarding realistic timelines prevents frustration and supports protocol compliance.

Strain matching between vaccines and field challenge viruses affects vaccine performance, and circulating coronavirus strains may differ antigenically from vaccine strains. The genetic diversity among PEDV strains, including highly virulent and variant strains with different spike protein sequences, presents challenges for vaccine development and selection. Diagnostic surveillance including virus characterization helps assess vaccine appropriateness for specific farm challenges. Autogenous vaccines offer strain-specific protection when commercial products inadequately match field viruses, though production timelines limit their utility in acute outbreak response.

Storage of TGE and PEDV vaccines requires consistent refrigeration at two to eight degrees Celsius from receipt through administration, with strict avoidance of both freezing and temperature elevation that compromise vaccine potency. Dedicated vaccine refrigerators with accurate temperature monitoring provide optimal storage conditions for these temperature-sensitive biological products. Thermometers capable of recording minimum and maximum temperatures, or continuous electronic monitoring systems, document storage condition maintenance and identify excursions requiring evaluation. Vaccines experiencing temperature excursions outside acceptable ranges should not be used regardless of visual appearance, as potency loss is not visually detectable.

Handling during vaccination sessions must maintain cold chain integrity while allowing efficient administration. Vaccines should be removed from refrigeration in quantities that can be used within manufacturer-specified timeframes, typically several hours, and protected from temperature extremes and direct sunlight during use. Coolers with ice packs maintain temperature during field conditions, though direct contact between vaccines and ice should be avoided to prevent freezing. Multi-dose vials should be gently mixed before drawing doses if components have settled, and aseptic technique should be maintained to prevent contamination of remaining doses.

Disposal of unused vaccine, empty vials, and administration equipment follows standard biological waste management practices. Unused vaccine should be disposed of according to local regulations, with inactivated products typically acceptable for standard waste streams after appropriate documentation. Empty vaccine vials may be disposed of as regular waste in most jurisdictions after thorough rinsing. Needles and syringes require placement in puncture-resistant sharps containers with disposal through licensed medical waste services. Vaccination equipment should be cleaned and maintained between uses according to manufacturer recommendations. Complete documentation including lot numbers, expiration dates, and disposal records supports quality assurance and traceability.

Commercial swine breeds utilized in modern pork production, including Yorkshire, Landrace, Duroc, Hampshire, and their crosses, respond similarly to TGE and PEDV vaccination without documented breed-specific differences in efficacy, adverse reactions, or maternal antibody transfer. Genetic selection in these populations has emphasized production traits including reproductive performance, growth rate, and carcass composition rather than immunological characteristics specific to coronavirus response. Vaccination protocols developed for commercial systems apply across these genetic lines without breed-specific modifications, with individual herd factors and management systems more significantly influencing program design than breed genetics.

Heritage and minor swine breeds maintained in alternative production systems have received limited formal evaluation regarding coronavirus vaccination but are expected to respond similarly to commercial genetics. Breeds including Berkshire, Red Wattle, Gloucestershire Old Spots, and others may be managed under conditions with different biosecurity standards and disease exposure patterns than intensive commercial production. Outdoor or pasture-based systems common with heritage breeds may face unique coronavirus introduction risks or may maintain isolation that reduces exposure. Vaccination decisions in these populations should consider actual disease risk assessment rather than assuming commercial protocols automatically apply.

Miniature pig breeds maintained as companion animals present unique considerations for coronavirus vaccination. These populations typically have limited exposure to other swine, reducing coronavirus transmission risk compared to commercial herds. However, owners who attend pig events, shows, or visit other pig-owning households may introduce coronavirus exposure risks. The decision to vaccinate companion pigs against TGE and PEDV should be based on individual risk assessment including exposure opportunities, local disease prevalence, and owner-specific circumstances. The neonatal mortality focus of commercial vaccination programs may not directly translate to companion pig contexts where breeding may not occur.

Production system characteristics influence coronavirus vaccination strategy more than breed genetics in most practical situations. Farrow-to-finish operations with on-site farrowing have different coronavirus dynamics than specialized breeding farms selling weaned pigs. Multi-site production with pig movement between locations creates introduction risks requiring robust sow vaccination programs. High-health systems maintaining coronavirus-negative status may elect against vaccination to preserve negative status and avoid vaccine interference with surveillance testing. The interaction between production system, biosecurity capability, disease pressure, and genetic background should guide individualized vaccination program design.

Autogenous coronavirus vaccines provide farm-specific protection using virus isolates obtained from the affected herd, offering theoretically optimal strain matching when commercial vaccines inadequately address circulating viruses. These custom products require submission of appropriate diagnostic samples to licensed biologics manufacturers, with virus isolation, characterization, and vaccine production spanning several weeks to months. While more expensive and logistically demanding than commercial vaccines, autogenous products address the antigenic diversity among circulating PEDV strains that may exceed commercial vaccine coverage. Combining autogenous and commercial vaccines may provide broader protection through complementary strain coverage.

Other enteric disease vaccines for swine address pathogens that may co-occur with or be confused with coronavirus infections. Escherichia coli vaccines targeting enterotoxigenic strains causing neonatal and post-weaning diarrhea protect against bacterial scours that can resemble viral enteritis. Clostridium perfringens type C vaccines prevent necrotic enteritis in neonatal piglets. Rotavirus vaccines address another viral cause of piglet diarrhea. Comprehensive neonatal enteric disease programs may combine coronavirus vaccination with these products, scheduling to optimize protection across multiple pathogens while avoiding immunological interference from simultaneous administration.

Non-vaccine interventions complement vaccination in comprehensive coronavirus control programs. Strict biosecurity measures including entry protocols, transport sanitation, and feed safety practices reduce virus introduction risk. Sanitation and disinfection programs using coronavirus-effective products eliminate environmental contamination. Controlled feedback exposure programs, while controversial, stimulate mucosal immunity more effectively than injectable vaccines alone in many field situations. Supportive care for affected piglets including electrolyte supplementation, thermal support, and management of secondary infections addresses immediate welfare while immunity develops. Recognition that vaccination alone cannot optimally control coronaviruses drives integrated program design addressing multiple intervention points.